Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoon Jong Choi

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Oncotarget|April 9, 2013
Unexpected outcomes of CDK4/6 inhibitionYoon Jong Choi, Piotr Sicinski
NAR Cancer|July 31, 2023
CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombinationVictoria E Brown, Sydney L Moore, Maxine Chen, et al.
Cancer Cell|October 20, 2012
The requirement for cyclin D function in tumor maintenanceYoon Jong Choi, Xiaoyu Li, Per Hydbring, et al.
Cancer Research|February 13, 2025
Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial TumorsNealia C House, Victoria E Brown, Maxine Chen, et al.
Developmental Cell|August 5, 2014
D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasLYoon Jong Choi, Borja Saez, Lars Anders, et al.
Nature|May 30, 2014
Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progressionYoonjin Lee, John E Dominy, Yoon Jong Choi, et al.
Cancer Research|May 9, 2019
Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7Shanhu Hu, Jason J Marineau, Nisha Rajagopal, et al.
Cancer Cell|April 12, 2017
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory CancersPer Hydbring, Yinan Wang, Anne Fassl, et al.
Journal of Medicinal Chemistry|July 30, 2024
Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase InhibitorsJack R Davison, Michalis Hadjithomas, Stuart P Romeril, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Oncotarget|April 9, 2013
Unexpected outcomes of CDK4/6 inhibitionYoon Jong Choi, Piotr Sicinski
NAR Cancer|July 31, 2023
CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombinationVictoria E Brown, Sydney L Moore, Maxine Chen, et al.
Cancer Cell|October 20, 2012
The requirement for cyclin D function in tumor maintenanceYoon Jong Choi, Xiaoyu Li, Per Hydbring, et al.
Cancer Research|February 13, 2025
Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial TumorsNealia C House, Victoria E Brown, Maxine Chen, et al.
Developmental Cell|August 5, 2014
D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasLYoon Jong Choi, Borja Saez, Lars Anders, et al.
Nature|May 30, 2014
Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progressionYoonjin Lee, John E Dominy, Yoon Jong Choi, et al.
Cancer Research|May 9, 2019
Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7Shanhu Hu, Jason J Marineau, Nisha Rajagopal, et al.
Cancer Cell|April 12, 2017
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory CancersPer Hydbring, Yinan Wang, Anne Fassl, et al.
Journal of Medicinal Chemistry|July 30, 2024
Genomic Discovery and Structure-Activity Exploration of a Novel Family of Enzyme-Activated Covalent Cyclin-Dependent Kinase InhibitorsJack R Davison, Michalis Hadjithomas, Stuart P Romeril, et al.
Pageof 1